PNP Technology
Canadian Medstore has developed a comprehensive patent portfolio based on its proprietary PNP technology. This collection includes numerous patent applications that target various innovations within this field. Specifically, these applications encompass inventions related to the composition and use of PNPs, as well as specialized devices and methods for their production.
CDP Technology
The pharmacy holds an exclusive license to the patent estates from the California Institute of Technology and Calando Pharmaceuticals, providing extensive international protection for its CDP technology platform and its various applications. Additional patent applications from our pharmacy cover enhancements and novel uses of the CDP technology, with a strong focus on the lead product candidate and related inventions.
Nano-Pharmaceutical Development Expertise
Canadian Medstore possesses unique capabilities essential for the development of nano-pharmaceuticals. In a short period, the pharmacy has developed a range of proprietary technologies and in-licensed complementary methods. These technologies are capable of incorporating different classes of drugs and have been validated in multiple pre-clinical cancer models. Furthermore, the pharmacy has established a sophisticated set of analytical and bioanalytical instruments crucial for the development and optimization of its nanoparticle-based therapies.
Clinical Candidate Progress
Our Canadian pharmacy has accumulated significant clinical development experience by advancing one of the pioneering nanoparticles into clinical trials. This clinical candidate has demonstrated safety in human use and has shown the ability to overcome toxicities and DMPK challenges that previously impeded the development of free camptothecin. Additionally, early signs of clinical activity have been observed. The Maximum Tolerated Dose (MTD) will be determined as part of the ongoing Phase 1b/2a clinical study.